We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Valneva SE | EU:VLA | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.054 | 1.60% | 3.434 | 3.432 | 3.434 | 3.492 | 3.36 | 3.40 | 312,038 | 16:39:17 |
From Nov 2023 to May 2024
By Stephen Nakrosis
The Food and Drug Administration said it granted approval of Ixchiq, the first vaccine for chikungunya virus, to Valneva Austria.
Valneva Austria's parent company is France's Valneva SE.
The FDA said Thursday chikungunya is a mosquito-borne disease, which causes symptoms including headache, fever, joint pain and rash. The virus is an emerging global health threat, with at least 5 million cases of infection reported over the past 15 years, according to the FDA.
Ixchiq was approved for those 18 years of age and older who are at increased risk of exposure to chikungunya virus, the FDA said.
Trade in Valneva's America depositary receipts was halted after hours Thursday because of pending news.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 09, 2023 18:20 ET (23:20 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Valneva Chart |
1 Month Valneva Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
